ZIOPHARM Oncology (NASDAQ:ZIOP) Sees Large Volume Increase

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) saw an uptick in trading volume on Friday . 6,914,281 shares traded hands during trading, an increase of 286% from the previous session’s volume of 1,792,205 shares.The stock last traded at $5.83 and had previously closed at $5.74.

A number of research firms have recently weighed in on ZIOP. BidaskClub raised ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research note on Monday, June 17th. HC Wainwright reissued a “buy” rating and set a $5.50 price objective on shares of ZIOPHARM Oncology in a research note on Thursday, May 9th. Zacks Investment Research lowered ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research note on Saturday, May 18th. Lake Street Capital began coverage on ZIOPHARM Oncology in a research note on Thursday, April 4th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Laidlaw began coverage on ZIOPHARM Oncology in a research note on Monday, April 1st. They set a “buy” rating and a $7.50 price objective for the company. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $5.75.

The business has a 50 day simple moving average of $4.76. The company has a quick ratio of 8.89, a current ratio of 8.89 and a debt-to-equity ratio of 0.01.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. On average, analysts predict that ZIOPHARM Oncology Inc. will post -0.33 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in ZIOPHARM Oncology by 12.3% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 52,871 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 5,802 shares during the period. Legal & General Group Plc lifted its stake in ZIOPHARM Oncology by 30.6% in the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 6,054 shares during the period. SG Americas Securities LLC lifted its stake in ZIOPHARM Oncology by 30.8% in the first quarter. SG Americas Securities LLC now owns 31,906 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 7,506 shares during the period. Northern Trust Corp lifted its stake in ZIOPHARM Oncology by 0.5% in the fourth quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock worth $3,081,000 after acquiring an additional 8,068 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in ZIOPHARM Oncology in the first quarter worth $35,000. 38.51% of the stock is owned by institutional investors.

ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

See Also: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.